Preoperative Blood Inflammatory Markers for the Differentiation of Uterine Leiomyosarcoma from Leiomyoma

References

• Nishigaya Y, Kobayashi Y, Matsuzawa Y, et al. Diagnostic value of combination serum assay of lactate dehydrogenase, D‐dimer, and C‐reactive protein for uterine leiomyosarcoma. J Obstet Gynaecol Res. 2019;45(1):189–194. doi:10.1111/jog.1379230152048
   PubMed Web of Science ®Google Scholar
• Cui RR, Wright JD. Risk of occult uterine sarcoma in presumed uterine fibroids. Clin Obstet Gynecol. 2016;59(1):103–118. doi:10.1097/GRF.000000000000016326645385
   PubMed Web of Science ®Google Scholar
• Cho HY, Kim K, Kim YB, No JH. Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. J Obstet Gynaecol Res. 2016;42(3):313–318. doi:10.1111/jog.1291526695124
   PubMed Web of Science ®Google Scholar
• Zhang G, Yu X, Zhu L, Fan Q, Shi H, Lang J. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid. BMC Cancer. 2020;20:1–7.
   Web of Science ®Google Scholar
• Eo WK, Chang HJ, Kwon SH, et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer. J Cancer. 2016;7(3):289. doi:10.7150/jca.1343226918042
   PubMed Web of Science ®Google Scholar
• Eo WK, Kwon S, Koh SB, et al. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of endometrial cancer. J Cancer. 2016;7(5):538. doi:10.7150/jca.1420627053952
   PubMed Web of Science ®Google Scholar
• Chun S, Shin K, Kim KH, et al. The neutrophil-lymphocyte ratio predicts recurrence of cervical intraepithelial neoplasia. J Cancer. 2017;8(12):2205. doi:10.7150/jca.1917328819422
   PubMed Web of Science ®Google Scholar
• Eo WK, Kim KH, Park EJ, et al. Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses. J Cancer. 2018;9(7):1165. doi:10.7150/jca.2360629675097
   PubMed Web of Science ®Google Scholar
• Kwon BS, Jeong DH, Byun JM, et al. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. J Cancer. 2018;9(7):1127. doi:10.7150/jca.2405729675093
   PubMed Web of Science ®Google Scholar
• Yapar A, Ulucaköy C, Sezgin EA, Atalay İB, Ekşioğlu MF. Diagnostic role of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in patients with enchondroma and low-grade chondrosarcoma. Joint Dis Relat Surg. 2020;31(2):286. doi:10.5606/ehc.2020.73629
   PubMedGoogle Scholar
• Jeong MJ, Park JH, Hur SY, Kim CJ, Nam HS, Lee YS. Preoperative neutrophil-to-lymphocyte ratio as a prognostic factor in uterine sarcoma. J Clin Med. 2020;9(9):2898. doi:10.3390/jcm9092898
   PubMed Web of Science ®Google Scholar
• Gallicchio L, Harvey LA, Kjerulff KH. Fear of cancer among women undergoing hysterectomy for benign conditions. Psychosom Med. 2005;67(3):420–424. doi:10.1097/01.psy.0000160472.69303.5615911905
   PubMed Web of Science ®Google Scholar
• Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol. 2017;145(1):208–216. doi:10.1016/j.ygyno.2017.02.01928209496
   PubMed Web of Science ®Google Scholar
• Skorstad M, Kent A, Lieng M. Uterine leiomyosarcoma–incidence, treatment, and the impact of morcellation. A nationwide cohort study. Acta Obstet Gynecol Scand. 2016;95(9):984–990. doi:10.1111/aogs.1293027223683
   PubMed Web of Science ®Google Scholar
• Köhler G, Vollmer M, Nath N, et al. Benign uterine mass—discrimination from leiomyosarcoma by a preoperative risk score: a multicenter cohort study. Arch Gynecol Obstet. 2019;300(6):1719–1727. doi:10.1007/s00404-019-05344-031677088
   PubMed Web of Science ®Google Scholar
• Valzacchi GMR, Rosas P, Uzal M, Gil SJ, Viglierchio VT. Incidence of leiomyosarcoma at surgery for presumed uterine myomas in different age groups. J Minim Invasive Gynecol. 2020;27(4):926–929. doi:10.1016/j.jmig.2019.06.01331260748
   PubMed Web of Science ®Google Scholar
• Multinu F, Casarin J, Tortorella L, et al. Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study. Am J Obstet Gynecol. 2019;220(2):179.e1–e10. doi:10.1016/j.ajog.2018.11.1086
   PubMed Web of Science ®Google Scholar
• Lawlor H, Ward A, Maclean A, et al. Developing a preoperative algorithm for the diagnosis of uterine leiomyosarcoma. Diagnostics. 2020;10(10):735. doi:10.3390/diagnostics10100735
   Web of Science ®Google Scholar
• DeMulder D, Ascher SM. Uterine leiomyosarcoma: can MRI differentiate leiomyosarcoma from benign leiomyoma before treatment? Am J Roentgenol. 2018;211(6):1405–1415. doi:10.2214/AJR.17.1923430354268
   PubMed Web of Science ®Google Scholar
• Lee JW, Park JY, Lee HJ, et al. Preoperative [18 F] FDG PET/CT tumour heterogeneity index in patients with uterine leiomyosarcoma: a multicentre retrospective study. Eur J Nucl Med Mol Imaging. 2018;45(8):1309–1316. doi:10.1007/s00259-018-3975-629492644
   PubMed Web of Science ®Google Scholar
• Nagai T, Takai Y, Akahori T, et al. Novel uterine sarcoma preoperative diagnosis score predicts the need for surgery in patients presenting with a uterine mass. Springerplus. 2014;3(1):678. doi:10.1186/2193-1801-3-67825520907
   PubMedGoogle Scholar
• Sun S, Bonaffini P, Nougaret S, et al. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging. 2019;100(10):619–634. doi:10.1016/j.diii.2019.07.00731427216
   PubMed Web of Science ®Google Scholar
• Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immunity Arch. 2007;7(1).
   Google Scholar
• Wang X, Liu S, Zhao X, Fang E, Zhao X. The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: a meta-analysis. PLoS One. 2019;14(7):e0219215. doi:10.1371/journal.pone.021921531260491
   PubMed Web of Science ®Google Scholar
• Glorie N, Baert T, Van Den Bosch T, Coosemans A. Circulating protein biomarkers to differentiate uterine sarcomas from leiomyomas. Anticancer Res. 2019;39(8):3981–3989. doi:10.21873/anticanres.1355331366479
   PubMed Web of Science ®Google Scholar
• Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353–363. doi:10.3233/CBM-16033628582845
   PubMed Web of Science ®Google Scholar
• Di Cello A, Borelli M, Marra ML, et al. A more accurate method to interpret lactate dehydrogenase (LDH) isoenzymes’ results in patients with uterine masses. Eur J Obstet Gynecol Reprod Biol. 2019;236:143–147. doi:10.1016/j.ejogrb.2019.03.01730925450
   PubMed Web of Science ®Google Scholar
• Mollo A, Raffone A, Travaglino A, et al. Increased LDH5/LDH1 ratio in preoperative diagnosis of uterine sarcoma with inconclusive MRI and LDH total activity but suggestive CT scan: a case report. BMC Womens Health. 2018;18(1):169. doi:10.1186/s12905-018-0662-530340636
   PubMed Web of Science ®Google Scholar
• El-Kenawi A, Hänggi K, Ruffell B. The immune microenvironment and cancer metastasis. Cold Spring Harb Perspect Med. 2020;10(4):a037424. doi:10.1101/cshperspect.a03742431501262
   PubMed Web of Science ®Google Scholar
• Kim HS, Han K, Chung HH, et al. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol. 2010;36(7):691–698. doi:10.1016/j.ejso.2010.05.00420570475
   PubMed Web of Science ®Google Scholar
• Fujibuchi T, Miyawaki J, Kidani T, Imai H, Miura H. Prediction of soft tissue sarcoma from clinical characteristics and laboratory data. Cancers. 2020;12(3):679. doi:10.3390/cancers12030679
   PubMed Web of Science ®Google Scholar
• Cong R, Kong F, Ma J, Li Q, Wu Q, Ma X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer. BMC Cancer. 2020;20:1–11. doi:10.1186/s12885-020-06953-8
   Web of Science ®Google Scholar
• Chen W, Zhong S, Shan B, et al. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. J Ovarian Res. 2020;13(1):89. doi:10.1186/s13048-020-00693-w32771026
   PubMed Web of Science ®Google Scholar
• Su S, Liu L, Li C, Zhang J, Li S. Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: a systematic review and meta-analysis. Int J Surg. 2019;72:146–153. doi:10.1016/j.ijsu.2019.10.04331707011
   PubMed Web of Science ®Google Scholar
• Baert T, Van Camp J, Vanbrabant L, et al. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol. 2018;150(1):31–37. doi:10.1016/j.ygyno.2018.05.00429751991
   PubMed Web of Science ®Google Scholar
• Wu J, Chen M, Liang C, Su W. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. Oncotarget. 2017;8(8):13400. doi:10.18632/oncotarget.1454128077792
   PubMed Web of Science ®Google Scholar
• Tezol O, Bozlu G, Sagcan F, Tuncel DF, Citak C. Value of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio and red blood cell distribution width in distinguishing between reactive lymphadenopathy and lymphoma in children. Bratisl Lek Listy. 2020;121(4):287. doi:10.4149/BLL_2020_04532356444
   PubMed Web of Science ®Google Scholar
• Zheng SH, Huang JL, Chen M, Wang BL, Ou QS, Huang SY. Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study. J Neurosurg. 2018;129(3):583–592. doi:10.3171/2017.3.JNS16164829099300
   PubMed Web of Science ®Google Scholar
• Çolak M, Eravcı FC, Karakurt SE, Karakuş MF, Ikincioğulları A, Özcan KM. The predictive value of neutrophil-to-lymphocyte ratio for Hodgkin’s lymphoma diagnosis in patients with asymptomatic cervical lymphadenopathy. Indian J Otolaryngol Head Neck Surg. 2019;71(1):986–991. doi:10.1007/s12070-019-01676-031742107
   PubMed Web of Science ®Google Scholar
• Adhyatma KP, Prapiska FF, Siregar GP, Warli SM. Systemic inflammatory response in predicting prostate cancer: the diagnostic value of neutrophil-to-lymphocyte ratio. Open Access Maced J Med Sci. 2019;7(10):1628. doi:10.3889/oamjms.2019.17731210812
   PubMedGoogle Scholar
• Zhou JG, Zhao HT, Jin SH, Tian X, Ma H. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma. Gynecol Oncol. 2019;155(3):499–507. doi:10.1016/j.ygyno.2019.08.03331662204
   PubMed Web of Science ®Google Scholar
• Cherniack AD, Shen H, Walter V, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell. 2017;31(3):411–423. doi:10.1016/j.ccell.2017.02.01028292439
   PubMed Web of Science ®Google Scholar